Update: Newsflow-rich period
BioLineRx has provided critical updates on key pipeline projects in recent weeks. It now plans to test a larger cohort at higher doses in its Phase II trial of BL-8040 in acute myeloid leukaemia on the back of encouraging efficacy/safety data presented at the ASH conference this week. Enrolment for the CE mark trial of Bioabsorbable Cardiac Matrix is expected to be completed by year end and study completion is slated for mid-2015. BioLineRx also recently announced positive Phase I/II safety data for BL-7010 in coeliac disease, enabling the start of a pivotal efficacy trial in 2015.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.